ClinicalTrials.gg
CompletedNCT02138773Updated Jul 16, 2014

A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects

A Phase 1 interventional study of Tamsulosin formulation-A and Tamsulosin formulation-B in Healthy and Pharmacokinetics of Tamsulosin Hydrochloride, sponsored by Astellas Pharma China, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-16.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the relative bioavailability of two types of prolonged release formulation of tamsulosin hydrochloride in Chinese healthy subjects. The safety of tamsulosin formulation is also compared.

Read the detailed description

There will be two studies. One study will be conducted under fed condition, and the other study will be conducted under fasted condition. Each study is a single center, randomized, single dose, open-labeled, cross-over study.

Study 1 will be conducted under fed condition:

Subjects will undergo screening evaluations to determine their eligibility within 7 days prior to the study enrollment. Subjects will be admitted to the clinical facility in the evening prior to dosing for each period. All subjects will receive tamsulosin formulation-A and formulation-B in one of two randomly assigned treatment sequences at 0.5h after the start of a standard breakfast. There will be a 7-day washout period between each dose.

Study 2 will be under fasted condition:

A single oral dose of tamsulosin formulation-A or formulation-B will be given to subjects under fasted condition (fasting for at least 10 hours since 20:00PM the night before the administration). Blood will be sampled at the same time point as in Study 1. Also, safety evaluation will be performed at the same selected times throughout the study as in Study 1.

02

Conditions studied

  • Healthy
  • Pharmacokinetics of Tamsulosin Hydrochloride

Keywords

  • prolonged release formulation
  • adrenergic blocker
  • Bioequivalence
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI=weight (kg)/height(m)2) between 19 and 24 (included)
  • Body weight no less than 50 kg
  • Healthy as determined by no deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations

Exclusion criteria

Exclusion Criteria:

  • Subject receiving drug treatment (including OTC) within 4 weeks prior to the first administration
  • Subject with a known or suspected history of allergic condition and/or to Tamsulosin, any in the drug product or drugs of the same class
  • Existing cardiac, haematological, hepatic, renal, gastrointestinal or any other acute or chronic disease and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics
  • Subject with symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20mmHg within two minutes when changing from the supine to the standing position
  • Subject with sitting DBP\<60mmHg or >90mmHg, and/or SBP\<90mmHg or>140mmHg, and/or pulse rate (PR) \<40/min or >90/min, and/or axilla temperature >37℃ or \<35℃ within the screen period
  • Subject with a previous history of drug abuse or subject showing any degree of drug abuse within 3 months prior to the present study
  • Subject with a blood donation or other plasma loss of more than 200mL or received a transfusion of any blood or blood products within 3 months prior to the start of the present study
  • Subject with a treatment of plasma exchange within 4 weeks prior to the present study
  • Subject participated in any other study within 3 months prior to the present study, or participated in more than 3 studies during the last 12 months prior to the start of the present study
  • Subject with HBs-Ag, -Ab or -Ab
  • Subject with a partner wish to become pregnant during the present study period and 30 days after the study
  • Subject is mentally or physically disabled
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Fed, formulation-A

    drug administered at 0.5h after the start of a standard breakfast

    Drug: Tamsulosin formulation-A

  • Experimental
    Fed, formulation-B

    drug administered at 0.5h after the start of a standard breakfast

    Drug: Tamsulosin formulation-B

  • Experimental
    Fasted, formulation-A

    drug administered under fasted condition (fasting for at least 10 hours)

    Drug: Tamsulosin formulation-A

  • Experimental
    Fasted, formulation-B

    drug administered under fasted condition (fasting for at least 10 hours)

    Drug: Tamsulosin formulation-B

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter of tamsulosin (AUC0-t)

    AUC0-t will be calculated according to the linear trapezoidal rule.

    Time frame: up to 72 hr after administration

  2. Pharmacokinetic parameter of tamsulosin (Cmax)

    Time frame: up to 72 hr after administration

Secondary outcomes

  1. Pharmacokinetic parameter of tamsulosin (AUC0-∞)

    Time frame: up to 72 hr after administration

  2. Pharmacokinetic parameter of tamsulosin (Tmax)

    Time frame: up to 72 hr after administration

  3. Pharmacokinetic parameter of tamsulosin (T1/2)

    Time frame: up to 72 hr after administration

  4. Safety evaluated by physical examinations, vital signs, electrocardiograms, laboratory assessments, and adverse events.

    Time frame: up to 72 hr after administration

07

Study locations

1 site
  • Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2014
First posted
May 15, 2014
Start
Apr 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jul 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02138773
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Apr 2014
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 16, 2014

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion